Olumiant
Active Ingredient(s): BaricitinibFDA Approved: * May 31, 2018
Pharm Company: * ELI LILLY AND CO
Category: Arthritis
Baricitinib, sold under the brand name Olumiant among others, is a drug for the treatment of rheumatoid arthritis (RA) in adults whose disease was not well controlled by tumor necrosis factor (TNF) inhibitors.[6] It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.[7] The drug is approved for medical use in the European Union[5] and in the United States.[6][8] An important side effec... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.